Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderately to Severely Active Ulcerative Colitis Clear all
Not yet recruiting Phase 2 Interventional

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT07513181
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Interventions
ATH-063, Placebo
Drug · Other
Lead sponsor
Athos Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida • Roswell, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

TD-1473 for Active Ulcerative Colitis (UC)

NCT02818686
View directory record Official record
Conditions
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
TD-1473, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Monroe, Louisiana • Hermitage, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 4 Interventional Results available

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

NCT03029143
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
44
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 26, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

NCT06109441
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-268
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
San Diego, California • Littleton, Colorado • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

NCT04504383
View directory record Official record
Conditions
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
PN-943, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Tucson, Arizona • Garden Grove, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jun 26, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03616821
View directory record Official record
Conditions
Ulcerative Colitis, IBD
Interventions
Brazikumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Anaheim, California • Colorado Springs, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional Results available

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

NCT03169894
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
MDGN-002
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Hialeah, Florida • New Port Richey, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT01959282
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily, JNJ-54781532 75 mg twice daily
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jun 26, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
20
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
58
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02914522
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, PTM filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jun 26, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib Fosmecarbil, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
53
States / cities
Sun City, Arizona • Chula Vista, California • Coronado, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

NCT05507203
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
64
States / cities
Dothan, Alabama • Guntersville, Alabama • Sun City, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 26, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
Interventions
SPY001, SPY002, SPY003, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Canoga Park, California • La Jolla, California • Lancaster, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03653026
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
114
States / cities
Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jun 26, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT01988961
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
La Jolla, California • National City, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Jun 26, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

NCT05084261
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BT051 200 mg, BT051 800 mg, BT051 3200 mg, Matching Placebo
Drug
Lead sponsor
Adiso Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Rialto, California • Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Jun 26, 2026, 1:27 AM EDT